Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 May;19(5):613–618. doi: 10.1111/j.1365-2125.1985.tb02688.x

Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure.

P Ghirardi, B Brusoni, M Mangiavacchi, L Bianco, J Col, M Metra, L Dei Cas
PMCID: PMC1463844  PMID: 4005102

Abstract

Ten patients with congestive heart failure (CHF), in III and IV NYHA Class, were treated orally with a single dose of ibopamine ranging from 1.2-3.3 mg/kg, and were studied using the Swan-Ganz catheter and thermodilution technique. Cardiac index (CI) and stroke volume index (SVI) were increased, and mean pulmonary pressure (PAP), systemic vascular resistances (SVR) were lowered. Ibopamine increased CI (+33%) and SVI (+26%), and decreased PAP (-17%) and SVR (-24%). All changes were statistically significant. The maximum haemodynamic effect occurred 180 min after ibopamine administration. Blood pressure and heart rate were unaffected. Tolerability was good. This study shows that ibopamine when orally administered to human subjects improves cardiac performance and further investigations on its use as a therapeutic agent in the long term treatment of CHF are recommended.

Full text

PDF
613

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beller G. A., Smith T. W., Abelmann W. H., Haber E., Hood W. B., Jr Digitalis intoxication. A prospective clinical study with serum level correlations. N Engl J Med. 1971 May 6;284(18):989–997. doi: 10.1056/NEJM197105062841801. [DOI] [PubMed] [Google Scholar]
  2. Col J., Mievis E., Reynaert M. Ibopamine in very severe congestive heart failure: pilot haemodynamic invasive assessment. Eur J Clin Pharmacol. 1983;24(3):297–300. doi: 10.1007/BF00610044. [DOI] [PubMed] [Google Scholar]
  3. Davidson C., Gibson D. Clinical significance of positive inotropic action of digoxin in patients with left ventricular disease. Br Heart J. 1973 Sep;35(9):970–976. doi: 10.1136/hrt.35.9.970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dei Cas L., Bolognesi R., Cucchini F., Fappani A., Riva S., Visioli O. Hemodynamic effects of ibopamine in patients with idiopathic congestive cardiomyopathy. J Cardiovasc Pharmacol. 1983 Mar-Apr;5(2):249–253. doi: 10.1097/00005344-198303000-00014. [DOI] [PubMed] [Google Scholar]
  5. Dei Cas L., Manca C., Bernardini B., Vasini G., Visioli O. Noninvasive evaluation of the effects of oral ibopamine (SB 7505) on cardiac and renal function in patients with congestive heart failure. J Cardiovasc Pharmacol. 1982 May-Jun;4(3):436–440. doi: 10.1097/00005344-198205000-00014. [DOI] [PubMed] [Google Scholar]
  6. Dei Cas L., Manca C., Vasini G., Mansour M., Bernardini B., Visioli O. Non-invasive evaluation of left ventricular function through systolic time intervals following oral administration of SB 7505 in man. Arzneimittelforschung. 1980;30(3):498–500. [PubMed] [Google Scholar]
  7. Farah A. E., Alousi A. A. New cardiotonic agents: a search for digitalis substitute. Life Sci. 1978 Apr 3;22(13-15):1139–1147. doi: 10.1016/0024-3205(78)90083-8. [DOI] [PubMed] [Google Scholar]
  8. Finlay G. D., Whitsett T. L., Cucinell E. A., Goldberg L. I. Augmentation of sodium and potassium excretion, glomerular filtration rate and renal plasma flow by levodopa. N Engl J Med. 1971 Apr 15;284(15):865–870. doi: 10.1056/NEJM197104222841601. [DOI] [PubMed] [Google Scholar]
  9. Ghirardi P., Bauer R., Brusoni B. Effets d'un dérivé de la dopamine actif par voie orale sur l'excrétion rénale. Nouv Presse Med. 1980 Feb 9;9(7):453–453. [PubMed] [Google Scholar]
  10. Goldberg L. I., Hsieh Y. Y., Resnekov L. Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis. 1977 Jan-Feb;19(4):327–340. doi: 10.1016/0033-0620(77)90007-x. [DOI] [PubMed] [Google Scholar]
  11. Longhini C., Musacci G. F., Ansani L., Toselli T., Artioli M., Bianco L., Ghirardi P. Effect of ibopamine on peripheral haemodynamics. Eur J Clin Pharmacol. 1983;24(5):585–589. doi: 10.1007/BF00542205. [DOI] [PubMed] [Google Scholar]
  12. Melloni G. F., Melloni R., Minoja G. M., Scarazzati G., Bruni G. C., Loreti P., Bauer R. Clinical tolerability of ibopamine hydrochloride (SB 7505). Eur J Clin Pharmacol. 1981;19(6):409–411. doi: 10.1007/BF00548583. [DOI] [PubMed] [Google Scholar]
  13. Melloni G. F., Minoja G. M., Scorazzati G., Bauer R., Brusoni B., Ghirardi P. Renal effect of SB 7505: a double-blind study. Eur J Clin Pharmacol. 1981 Feb;19(3):177–180. doi: 10.1007/BF00561945. [DOI] [PubMed] [Google Scholar]
  14. Mengeot P., Piette F., Mirgaux M. Double-blind haemodynamic study of a new dopamine derivative (diisobutyric ester of N-methyl-dopamine) orally active in chronic congestive heart failure. G Ital Cardiol. 1981;11(11):1738–1742. [PubMed] [Google Scholar]
  15. Montani E., Triulzi M. O., Maggi G. C. Effect of ibopamine on heart rate and spontaneous premature ventricular beats in patients with angina pectoris. Eur J Clin Pharmacol. 1982;21(5):369–371. doi: 10.1007/BF00542320. [DOI] [PubMed] [Google Scholar]
  16. Nicaise J., Vryens R. Ibopamine in geriatric patients with cardiac and chronic renal failure: a clinical study. Farmaco Prat. 1982 Feb;37(2):65–70. [PubMed] [Google Scholar]
  17. Stefoni S., Colì L., Mosconi G., Prandini R. Ibopamine (SB 7505) in normal subjects and in chronic renal failure: a preliminary report. Br J Clin Pharmacol. 1981 Jan;11(1):69–72. doi: 10.1111/j.1365-2125.1981.tb01104.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Whitsett T. L., Goldberg L. I. Effects of levodopa on systolic preejection period, blood pressure, and heart rate during acute and chronic treatment of Parkinson's disease. Circulation. 1972 Jan;45(1):97–106. doi: 10.1161/01.cir.45.1.97. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES